Clinical practice guideline: Androgen therapy in women: An Endocrine Society clinical practice guideline

Margaret E. Wierman, Rosemary Basson, Susan R. Davis, Sundeep Khosla, Karen K. Miller, William Rosner, Nanette Santoro

Research output: Contribution to journalArticle

241 Citations (Scopus)

Abstract

Objective: The objective was to provide guidelines for the therapeutic use of androgens in women. Participants: The Task Force was composed of a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, six additional experts, a methodologist, and a medical writer. The Task Force received no corporate funding or remuneration. Evidence: The Task Force used systematic reviews of available evidence to inform its key recommendations. The Task Force used consistent language and graphical descriptions of both the strength of recommendation and the quality of evidence, using the recommendations of the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) group. The strength of a recommendation is indicated by the number 1 (strong recommendation, associated with the phrase "we recommend") or 2 (weak recommendation, associated with the phrase "we suggest"). The quality of the evidence is indicated by cross-filled circles, such that ⊕○○○ denotes very-low-quality evidence, ⊕⊕○○ low quality, ⊕⊕⊕○ moderate quality, and ⊕⊕⊕⊕ high quality. Each recommendation is followed by a description of the evidence. Consensus Process: Consensus was guided by systematic reviews of evidence and discussions during one group meeting, several conference calls, and e-mail communications. The drafts prepared by the task force with the help of a medical writer were reviewed successively by The Endocrine Society's CGS, Clinical Affairs Committee (CAC), and Executive Committee. The version approved by the CGS and CAC was placed on The Endocrine Society's web site for comments by members. At each stage of review, the Task Force received written comments and incorporated needed changes. Conclusions: We recommend against making a diagnosis of androgen deficiency in women at present because of the lack of a well-defined clinical syndrome and normative data on total or free testosterone levels across the lifespan that can be used to define the disorder. Although there is evidence for short-term efficacy of testosterone in selected populations, such as surgically menopausal women, we recommend against the generalized use of testosterone by women because the indications are inadequate and evidence of safety in long-term studies is lacking. A review of the data currently available is presented, and areas of future research are outlined. To formulate clinical guidelines for use of testosterone in women, additional information will be necessary. This includes defining conditions that, when not treated with androgens, have adverse health consequences to women; defining clinical and laboratory parameters that distinguish those with these conditions; and assessing the efficacy and long-term safety of androgen administration on outcomes that are important to women diagnosed with these conditions. This necessary clinical research cannot occur until the biological, physiological, and psychological underpinnings of the role of androgens in women and candidate disorders are further elucidated.

Original languageEnglish (US)
Pages (from-to)3697-3710
Number of pages14
JournalJournal of Clinical Endocrinology and Metabolism
Volume91
Issue number10
DOIs
StatePublished - Oct 2006

Fingerprint

Practice Guidelines
Androgens
Advisory Committees
Testosterone
Guidelines
Teleconferencing
Therapeutics
Consensus
Websites
Remuneration
Safety
Group Processes
Health
Postal Service
Therapeutic Uses
Communication
Language
Psychology
Research
Population

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Clinical practice guideline : Androgen therapy in women: An Endocrine Society clinical practice guideline. / Wierman, Margaret E.; Basson, Rosemary; Davis, Susan R.; Khosla, Sundeep; Miller, Karen K.; Rosner, William; Santoro, Nanette.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 91, No. 10, 10.2006, p. 3697-3710.

Research output: Contribution to journalArticle

Wierman, Margaret E. ; Basson, Rosemary ; Davis, Susan R. ; Khosla, Sundeep ; Miller, Karen K. ; Rosner, William ; Santoro, Nanette. / Clinical practice guideline : Androgen therapy in women: An Endocrine Society clinical practice guideline. In: Journal of Clinical Endocrinology and Metabolism. 2006 ; Vol. 91, No. 10. pp. 3697-3710.
@article{e51f83c60a6b4aa1ad9c7396d409da98,
title = "Clinical practice guideline: Androgen therapy in women: An Endocrine Society clinical practice guideline",
abstract = "Objective: The objective was to provide guidelines for the therapeutic use of androgens in women. Participants: The Task Force was composed of a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, six additional experts, a methodologist, and a medical writer. The Task Force received no corporate funding or remuneration. Evidence: The Task Force used systematic reviews of available evidence to inform its key recommendations. The Task Force used consistent language and graphical descriptions of both the strength of recommendation and the quality of evidence, using the recommendations of the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) group. The strength of a recommendation is indicated by the number 1 (strong recommendation, associated with the phrase {"}we recommend{"}) or 2 (weak recommendation, associated with the phrase {"}we suggest{"}). The quality of the evidence is indicated by cross-filled circles, such that ⊕○○○ denotes very-low-quality evidence, ⊕⊕○○ low quality, ⊕⊕⊕○ moderate quality, and ⊕⊕⊕⊕ high quality. Each recommendation is followed by a description of the evidence. Consensus Process: Consensus was guided by systematic reviews of evidence and discussions during one group meeting, several conference calls, and e-mail communications. The drafts prepared by the task force with the help of a medical writer were reviewed successively by The Endocrine Society's CGS, Clinical Affairs Committee (CAC), and Executive Committee. The version approved by the CGS and CAC was placed on The Endocrine Society's web site for comments by members. At each stage of review, the Task Force received written comments and incorporated needed changes. Conclusions: We recommend against making a diagnosis of androgen deficiency in women at present because of the lack of a well-defined clinical syndrome and normative data on total or free testosterone levels across the lifespan that can be used to define the disorder. Although there is evidence for short-term efficacy of testosterone in selected populations, such as surgically menopausal women, we recommend against the generalized use of testosterone by women because the indications are inadequate and evidence of safety in long-term studies is lacking. A review of the data currently available is presented, and areas of future research are outlined. To formulate clinical guidelines for use of testosterone in women, additional information will be necessary. This includes defining conditions that, when not treated with androgens, have adverse health consequences to women; defining clinical and laboratory parameters that distinguish those with these conditions; and assessing the efficacy and long-term safety of androgen administration on outcomes that are important to women diagnosed with these conditions. This necessary clinical research cannot occur until the biological, physiological, and psychological underpinnings of the role of androgens in women and candidate disorders are further elucidated.",
author = "Wierman, {Margaret E.} and Rosemary Basson and Davis, {Susan R.} and Sundeep Khosla and Miller, {Karen K.} and William Rosner and Nanette Santoro",
year = "2006",
month = "10",
doi = "10.1210/jc.2006-1121",
language = "English (US)",
volume = "91",
pages = "3697--3710",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "10",

}

TY - JOUR

T1 - Clinical practice guideline

T2 - Androgen therapy in women: An Endocrine Society clinical practice guideline

AU - Wierman, Margaret E.

AU - Basson, Rosemary

AU - Davis, Susan R.

AU - Khosla, Sundeep

AU - Miller, Karen K.

AU - Rosner, William

AU - Santoro, Nanette

PY - 2006/10

Y1 - 2006/10

N2 - Objective: The objective was to provide guidelines for the therapeutic use of androgens in women. Participants: The Task Force was composed of a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, six additional experts, a methodologist, and a medical writer. The Task Force received no corporate funding or remuneration. Evidence: The Task Force used systematic reviews of available evidence to inform its key recommendations. The Task Force used consistent language and graphical descriptions of both the strength of recommendation and the quality of evidence, using the recommendations of the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) group. The strength of a recommendation is indicated by the number 1 (strong recommendation, associated with the phrase "we recommend") or 2 (weak recommendation, associated with the phrase "we suggest"). The quality of the evidence is indicated by cross-filled circles, such that ⊕○○○ denotes very-low-quality evidence, ⊕⊕○○ low quality, ⊕⊕⊕○ moderate quality, and ⊕⊕⊕⊕ high quality. Each recommendation is followed by a description of the evidence. Consensus Process: Consensus was guided by systematic reviews of evidence and discussions during one group meeting, several conference calls, and e-mail communications. The drafts prepared by the task force with the help of a medical writer were reviewed successively by The Endocrine Society's CGS, Clinical Affairs Committee (CAC), and Executive Committee. The version approved by the CGS and CAC was placed on The Endocrine Society's web site for comments by members. At each stage of review, the Task Force received written comments and incorporated needed changes. Conclusions: We recommend against making a diagnosis of androgen deficiency in women at present because of the lack of a well-defined clinical syndrome and normative data on total or free testosterone levels across the lifespan that can be used to define the disorder. Although there is evidence for short-term efficacy of testosterone in selected populations, such as surgically menopausal women, we recommend against the generalized use of testosterone by women because the indications are inadequate and evidence of safety in long-term studies is lacking. A review of the data currently available is presented, and areas of future research are outlined. To formulate clinical guidelines for use of testosterone in women, additional information will be necessary. This includes defining conditions that, when not treated with androgens, have adverse health consequences to women; defining clinical and laboratory parameters that distinguish those with these conditions; and assessing the efficacy and long-term safety of androgen administration on outcomes that are important to women diagnosed with these conditions. This necessary clinical research cannot occur until the biological, physiological, and psychological underpinnings of the role of androgens in women and candidate disorders are further elucidated.

AB - Objective: The objective was to provide guidelines for the therapeutic use of androgens in women. Participants: The Task Force was composed of a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, six additional experts, a methodologist, and a medical writer. The Task Force received no corporate funding or remuneration. Evidence: The Task Force used systematic reviews of available evidence to inform its key recommendations. The Task Force used consistent language and graphical descriptions of both the strength of recommendation and the quality of evidence, using the recommendations of the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) group. The strength of a recommendation is indicated by the number 1 (strong recommendation, associated with the phrase "we recommend") or 2 (weak recommendation, associated with the phrase "we suggest"). The quality of the evidence is indicated by cross-filled circles, such that ⊕○○○ denotes very-low-quality evidence, ⊕⊕○○ low quality, ⊕⊕⊕○ moderate quality, and ⊕⊕⊕⊕ high quality. Each recommendation is followed by a description of the evidence. Consensus Process: Consensus was guided by systematic reviews of evidence and discussions during one group meeting, several conference calls, and e-mail communications. The drafts prepared by the task force with the help of a medical writer were reviewed successively by The Endocrine Society's CGS, Clinical Affairs Committee (CAC), and Executive Committee. The version approved by the CGS and CAC was placed on The Endocrine Society's web site for comments by members. At each stage of review, the Task Force received written comments and incorporated needed changes. Conclusions: We recommend against making a diagnosis of androgen deficiency in women at present because of the lack of a well-defined clinical syndrome and normative data on total or free testosterone levels across the lifespan that can be used to define the disorder. Although there is evidence for short-term efficacy of testosterone in selected populations, such as surgically menopausal women, we recommend against the generalized use of testosterone by women because the indications are inadequate and evidence of safety in long-term studies is lacking. A review of the data currently available is presented, and areas of future research are outlined. To formulate clinical guidelines for use of testosterone in women, additional information will be necessary. This includes defining conditions that, when not treated with androgens, have adverse health consequences to women; defining clinical and laboratory parameters that distinguish those with these conditions; and assessing the efficacy and long-term safety of androgen administration on outcomes that are important to women diagnosed with these conditions. This necessary clinical research cannot occur until the biological, physiological, and psychological underpinnings of the role of androgens in women and candidate disorders are further elucidated.

UR - http://www.scopus.com/inward/record.url?scp=33749572914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749572914&partnerID=8YFLogxK

U2 - 10.1210/jc.2006-1121

DO - 10.1210/jc.2006-1121

M3 - Article

C2 - 17018650

AN - SCOPUS:33749572914

VL - 91

SP - 3697

EP - 3710

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 10

ER -